Patents Assigned to Celldex Therapeutics, Inc.
-
Publication number: 20180171027Abstract: Provided herein are methods of treating cancers expressing specific biomarkers with HER3 and/or EGFR inhibitors, and provided herein are also biomarkers and uses thereof in determining likelihood of effective cancer treatment with HER3 and/or EGFR inhibitors. In one aspect, the disclosure provides methods for treating a cancer, comprising administering to a patient diagnosed with said cancer a therapeutically effective amount of a HER3 inhibitor, an EGFR inhibitor, or a combination of a HER3 inhibitor and an EGFR inhibitor. Also disclosed herein are kits comprising components for performing the methods for determining whether a patient diagnosed with cancer is indicated as likely to be responsive to treatment with a HER3 inhibitor and/or an EGFR inhibitor.Type: ApplicationFiled: April 15, 2016Publication date: June 21, 2018Applicant: Celldex Therapeutics, Inc.Inventors: Theresa Marie Lavallee, Diego Alvarado
-
Publication number: 20180057595Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein.Type: ApplicationFiled: March 15, 2016Publication date: March 1, 2018Applicant: Celldex Therapeutics, Inc.Inventors: Yan Yang, Sreekala Mandiyan, Brett Robinson, Lida Kimmel, Yaron Hadari, Timothy David Jones, Francis Joseph Carr, Robert George Edward Holgate, Richard Weldon
-
Publication number: 20170158778Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.Type: ApplicationFiled: February 15, 2017Publication date: June 8, 2017Applicant: CELLDEX THERAPEUTICS, INC.Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
-
Patent number: 9649357Abstract: A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).Type: GrantFiled: March 16, 2016Date of Patent: May 16, 2017Assignees: CELLDEX THERAPEUTICS, INC., UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Richard J. H. Smith, Yuzhou Zhang, Henry C. Marsh
-
Patent number: 9649356Abstract: A method is disclosed for inhibiting complement activation in brain-dead organ donors, particularly kidney donors, which leads to improvement of organ function of transplanted organs in recipients. The method involves administration of a complement inhibitory protein, specifically a soluble complement receptor type I (sCR1) polypeptide to the donor prior to harvesting the organ for transplant.Type: GrantFiled: October 27, 2011Date of Patent: May 16, 2017Assignee: CELLDEX THERAPEUTICS, INC.Inventor: Marc Antonius Seelen
-
Patent number: 9624300Abstract: Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.Type: GrantFiled: December 17, 2012Date of Patent: April 18, 2017Assignee: Celldex Therapeutics Inc.Inventors: Tibor Keler, Lizhen He, Venky Ramakrishna, Laura A. Vitale
-
Patent number: 9605081Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.Type: GrantFiled: March 30, 2016Date of Patent: March 28, 2017Assignee: CELLDEX THERAPEUTICS, INC.Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
-
Patent number: 9580503Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: GrantFiled: November 29, 2011Date of Patent: February 28, 2017Assignees: Celldex Therapeutics, Inc., Amgen Fremont Inc.Inventors: Gregory M. Landes, Francine Chen, Binyam Bezabeh, Ian Foltz, Kam Fai Tse, Michael Jeffers, Mehdi Mesri, Gary Starling, Peter Mezes, Nikolia Khramtsov
-
Patent number: 9295713Abstract: A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).Type: GrantFiled: September 15, 2011Date of Patent: March 29, 2016Assignees: CELLDEX THERAPEUTICS, INC., UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Richard J. H. Smith, Yuzhou Zhang, Henry C. Marsh
-
Patent number: 9259459Abstract: The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (?hCG) antigen linked to an anti-mannose receptor (MR) antibody.Type: GrantFiled: July 30, 2004Date of Patent: February 16, 2016Assignee: Celldex Therapeutics Inc.Inventors: Tibor Keler, Michael Endres, Lizhen He, Venky Ramakrishna
-
Patent number: 9243064Abstract: The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (?hCG) antigen linked to an anti-mannose receptor (MR) antibody.Type: GrantFiled: January 30, 2004Date of Patent: January 26, 2016Assignee: Celldex Therapeutics Inc.Inventors: Tibor Keler, Michael Endres, Lizhen He, Venky Ramakrishna
-
Patent number: 9169325Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.Type: GrantFiled: April 13, 2011Date of Patent: October 27, 2015Assignee: Celldex Therapeutics, Inc.Inventors: Tibor Keler, Henry C. Marsh, Lizhen He, Laura A. Vitale, Lawrence J. Thomas
-
Patent number: 9095626Abstract: Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: February 15, 2012Date of Patent: August 4, 2015Assignee: CELLDEX THERAPEUTICS, INC.Inventors: Yashwant M. Deo, Tibor Keler, John Treml, Michael Endres
-
Patent number: 9051615Abstract: Disclosed are methods of detecting and treating tuberous sclerosis complex associated disorders. Also disclosed are methods of identifying agents for treating tuberous sclerosis complex associated disorders.Type: GrantFiled: May 2, 2012Date of Patent: June 9, 2015Assignee: Celldex Therapeutics, Inc.Inventors: Luca Rastelli, Bonnie Gould-Rothberg, Ryan Murphey
-
Patent number: 8846873Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.Type: GrantFiled: January 20, 2012Date of Patent: September 30, 2014Assignees: Celldex Therapeutics, Inc., Amgen Fremont, Inc.Inventors: Feng Xiao, Xiao-Chi Jia, Meina Liang, Orit Foord, Scott Klakamp, Kam Fai Tse, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael Jeffers, William LaRochelle, Gulshan Ara, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
-
Patent number: 8664176Abstract: A method is disclosed for treating diseases or disorders of the eye involving undesired neovascularization by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1). The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering a complement inhibitory protein intraocularly or systemically.Type: GrantFiled: October 19, 2007Date of Patent: March 4, 2014Assignee: Celldex Therapeutics, Inc.Inventors: Henry C. Marsh, Lawrence Thomas, Hua Gao, Xiaoxi Qiao
-
Patent number: 8586720Abstract: Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.Type: GrantFiled: July 6, 2012Date of Patent: November 19, 2013Assignee: Celldex Therapeutics Inc.Inventors: Tibor Keler, Lizhen He, Venky Ramakrishna, Laura A. Vitale
-
Publication number: 20130202527Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: ApplicationFiled: April 15, 2013Publication date: August 8, 2013Applicant: Celldex Therapeutics, Inc.Inventor: Celldex Therapeutics, Inc.
-
Publication number: 20130101593Abstract: Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: December 17, 2012Publication date: April 25, 2013Applicant: CELLDEX THERAPEUTICS INC.Inventor: Celldex Therapeutics Inc.
-
Publication number: 20130034573Abstract: The present disclosure relates to vaccine compositions, particularly KLH-peptide conjugates, and methods of making such compositions. The present disclosure further relates to methods of reducing abnormal cell growth using the composistions described herein.Type: ApplicationFiled: December 8, 2010Publication date: February 7, 2013Applicant: CELLDEX THERAPEUTICS, INC.Inventors: Syed Saleem Ahmed, John Joseph Buckley, III, Lavinia Marina Lewis, Brandi Rae Osborne, Sandipan Sinha, Jennifer Marie Thorn, Ferhana Zaman